News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
695,780 Results
Type
Article (41386)
Company Profile (420)
Press Release (653974)
Section
Business (208171)
Career Advice (1992)
Deals (35928)
Drug Delivery (87)
Drug Development (83198)
Employer Resources (168)
FDA (16283)
Job Trends (15027)
News (351525)
Policy (32962)
Tag
Academia (2618)
Africa (730)
Alliances (50527)
Alzheimer's disease (1203)
Approvals (16207)
Arizona (186)
Artificial intelligence (92)
Asia (38259)
Australia (6345)
Bankruptcy (360)
Best Places to Work (11545)
Biotechnology (317)
Breast cancer (77)
C2C Services and Suppliers (79621)
California (2204)
Canada (1021)
Cancer (644)
Career advice (1661)
Cell therapy (162)
China (167)
Clinical research (65210)
Collaboration (209)
Colorado (89)
Compensation (113)
Connecticut (93)
COVID-19 (2559)
Cystic fibrosis (82)
Data (483)
Diabetes (101)
Diagnostics (6066)
Drug pricing (80)
Earnings (84919)
Employer resources (143)
Europe (83294)
Events (111509)
Executive appointments (188)
FDA (16591)
Florida (312)
Funding (195)
Gene therapy (118)
Georgia (69)
GLP-1 (559)
Government (4391)
Healthcare (18943)
Hotbed/Location (488250)
Illinois (285)
Indiana (157)
Infectious disease (2600)
Inflammatory bowel disease (99)
Interviews (306)
IPO (16494)
Job creations (3691)
Job search strategy (1424)
Kansas (96)
Layoffs (427)
Legal (7911)
Lung cancer (126)
Manufacturing (114)
Maryland (452)
Massachusetts (1843)
Medical device (13222)
Medtech (13227)
Mergers & acquisitions (19343)
Metabolic disorders (306)
Michigan (132)
Minnesota (233)
Neuroscience (1395)
New Jersey (666)
New York (680)
NextGen Class of 2024 (6707)
Non-profit (4525)
North Carolina (668)
Northern California (937)
Obesity (184)
Ohio (116)
Opinion (189)
Patents (81)
Pennsylvania (637)
People (57295)
Pharmaceutical (81)
Phase I (20387)
Phase II (28769)
Phase III (21335)
Pipeline (142)
Postmarket research (2587)
Preclinical (8726)
Radiopharmaceuticals (246)
Rare diseases (161)
Real estate (5991)
Regulatory (21723)
Research institute (2400)
Resumes & cover letters (349)
South America (1104)
Southern California (877)
Startups (3745)
Texas (286)
United States (9840)
Vaccines (510)
Washington State (280)
Weight loss (152)
Date
Today (74)
Last 7 days (675)
Last 30 days (2779)
Last 365 days (37705)
2024 (28350)
2023 (41013)
2022 (52277)
2021 (56765)
2020 (54924)
2019 (47419)
2018 (35697)
2017 (33026)
2016 (32346)
2015 (38396)
2014 (32185)
2013 (27110)
2012 (29220)
2011 (29863)
2010 (27992)
695,780 Results for "vivace therapeutics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Drug Development
Our Mission at Voyager Therapeutics: Define the Future of Neurogenetic Medicines
We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system
May 8, 2024
·
2 min read
·
Voyager Therapeutics, Inc.
Biotech Bay
Vivace Therapeutics to Unveil First Clinical Data for a Cancer Drug Targeting the Hippo Pathway
Vivace Therapeutics, Inc. today announced that the first clinical data for a cancer treatment targeting the Hippo pathway will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2022.
March 15, 2023
·
2 min read
Biotech Bay
Researchers Report Clinical Proof-of-Concept Data for Vivace Therapeutics’ VT3989, a First for a Cancer Drug Targeting the Hippo Pathway, in Oral Presentation at AACR 2023
Vivace Therapeutics, Inc. announced that the first clinical data for a cancer treatment targeting the Hippo pathway was presented at the American Association for Cancer Research Annual Meeting 2023.
April 16, 2023
·
5 min read
Business
Gain Therapeutics, Inc. Appoints Gene Mack as Interim CEO
Gain Therapeutics, Inc. announces that Matthias Alder has departed the Company in order to pursue other opportunities.
June 27, 2024
·
5 min read
Press Releases
ReCerise Therapeutics Inc. Selected for Government Project by MOTIE
Initiates Development of Tailored Innovative Targeted Therapy for Refractory Cancer ReCerise Therapeutics Inc., has announced its selection for a grant from the Ministry of Trade, Industry and Energy of South Korea.
July 1, 2024
·
2 min read
Pharm Country
Click Therapeutics Accelerates Expansion into Obesity and Cardiometabolic Disease With Acquisition of the Assets of Better Therapeutics, Inc.
Click Therapeutics, Inc. (“Click”), a leader in Digital Therapeutics™ as prescription medical treatments, today announced plans to accelerate its development initiatives in obesity and cardiometabolic disease through the acquisition of the assets of Better Therapeutics, Inc.
May 22, 2024
·
7 min read
Press Releases
Qualigen Therapeutics, Inc. Announces management changes.
September 27, 2024
·
3 min read
Deals
Agile Therapeutics Inc. Announces Definitive Merger Agreement with Insud Pharma, S.L.
Agile Therapeutics, Inc. today announced that it has entered into a definitive merger agreement (“Merger Agreement”) with Insud Pharma, S.L.
June 26, 2024
·
10 min read
Drug Development
Nipocalimab pivotal Phase 3 trial demonstrates longest sustained disease control in FcRn class for broadest population of myasthenia gravis patients
Johnson & Johnson (NYSE: JNJ) today announced positive results from the nipocalimab Phase 3 Vivacity-MG3 study in patients with generalized myasthenia gravis (gMG).
June 28, 2024
·
12 min read
Biotech Bay
CERo Therapeutics, Inc. Completes IND-Enabling Activities Following Successful Manufacturing Runs for Lead Compound CER-1236
CERo Therapeutics Holdings, Inc., an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, announced it successfully executed pre-IND manufacturing activities for its lead therapeutic, CER-1236.
June 13, 2024
·
4 min read
1 of 69,578
Next
